Immunic (IMUX) Operating Expenses (2013 - 2026)

Immunic has disclosed Operating Expenses across 14 years of filings, most recently posting $33.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $33.2 million, up 23.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $109.6 million (up 8.56% YoY), and the FY2025 annual result was $103.2 million, up 5.28% from the prior year.
• Operating Expenses came in at $33.2 million for Q1 2026 at Immunic, up from $23.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $57.3 million in Q4 2022 to a low of $20.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $25.0 million (2023), against an average of $26.7 million.
• Across the five-year window, Operating Expenses surged 163.92% in 2022 and sank 59.21% in 2023, its largest moves.
• Immunic's Operating Expenses stood at $57.3 million in 2022, then tumbled by 59.21% to $23.4 million in 2023, then grew by 9.62% to $25.6 million in 2024, then dropped by 8.99% to $23.3 million in 2025, then surged by 42.47% to $33.2 million in 2026.
• The last three Operating Expenses figures came in at $33.2 million (Q1 2026), $23.3 million (Q4 2025), and $26.0 million (Q3 2025), per Business Quant data.